At Helus Pharma, we strategically innovate novel serotonergic agonists (NSAs) that set new standards in mental health, for conditions such as depression and anxiety. Our cutting-edge research, clinical excellence, and commitment to patient-centered innovation empowers individuals to durable recovery.

We are conducting clinical trials to evaluate these novel therapies designed to address the unmet needs of individuals seeking better treatment options. In our clinical trials, participants have the opportunity to contribute to paradigm shifting research that could change the future of mental health care. We are currently investigating HLP003¹, a proprietary deuterated NSA, in Phase 3 trials, which has shown promise in earlier studies to quickly and sustainably improve symptoms of depression. Additionally, we are advancing the development of HLP004², a proprietary deuterated NSA molecule being studied for its potential to improve symptoms of anxiety disorders.

These investigational medicines are not currently approved to be sold in any country. The purpose of these trials is to show that they are safe and effective. Participation not only helps us advance science but also brings us one step closer to providing new hope for those struggling with mental health challenges. Each trial is conducted in close collaboration with healthcare professionals and under rigorous safety standards to ensure participants’ well-being throughout the process.

Notes:
1 – Formerly referred to as CYB003
2- Formerly referred to as CYB004